Navigation Links
GeoPharma to Present at EdgeWater Research Partners Conference
Date:4/8/2008

Largo, Fla., April 8, 2008 /PRNewswire-FirstCall/ -- GeoPharma, Inc. (Nasdaq: GORX) announced that the company will present today at the EdgeWater Research Partners Spring Conference being held at the Grand Hyatt in Denver, Colorado at 2:25 MT.

"We are thoroughly pleased to have GeoPharma present at the spring conference," said EdgeWater President David Lavigne. "GeoPharma has a unique story with a thriving Manufacturing and Distribution business. We expect further positive developments in their Specialty Pharma business with several antibiotic drugs soon to enter into production. Furthermore, the continued development of their Early Stage Ovarian Cancer Diagnostic Device and the value it may add if approved, has not been factored into their current valuation."

EdgeWater Research Partners recently issued a Quarterly update to their Initial Coverage Report on GeoPharma which is currently the featured report on the GeoPharma website. The EdgeWater report and other research reports can be found on the Investor Relations Home Page at http://www.GeoPharmainc.com .

ABOUT EDGEWATER RESEARCH PARTNERS LLC:

EdgeWater Research Partners LLC. is an independent subscription based micro cap stock research company. Subscribers receives a monthly micro cap stock newsletter, in addition to individual company research reports and updates similar to the one's issued on GeoPharma. Annual subscriptions to EdgeWater Research services are available at http://www.edgewaterresearch.com

ABOUT GEOPHARMA, INC.:

GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversified business model participating in 3 main market segments: Specialty Pharma, Manufacturing, and Distribution. The Specialty Pharma division specializes in the formulation of generic drugs for human and veterinary usage and the development of medical devices used by oncologists and other medical professionals. The Manufacturing and Distribution divisions, manufacture, package, and distribute generic drugs, nutraceuticals, cosmetics, and functional food products for companies worldwide.

GeoPharma's growth strategy is to capitalize on its research and manufacturing expertise to develop medical devices and high margin generic drug products for niche markets with high barriers to entry. GeoPharma's competitive advantage in these areas is in its ability to navigate the challenges that such market pursuits present effectively.

Currently GeoPharma employs nearly 300 people and operates facilities in Florida, Maryland, Pennsylvania, Nevada, Rhode Island, and Texas utilizing over 330,000 Sq. Ft. of office, warehouse, manufacturing and laboratory facilities.

For further information visit the GeoPharma website at http://www.GeoPharmainc.com.

FORWARD-LOOKING STATEMENTS

This press release may contain statements, which constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission.


'/>"/>
SOURCE GeoPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeoPharma Announces Record Revenues in Third Quarter Results
2. GeoPharma Announces Third Quarter Conference Call
3. GeoPharma, Inc. Receives FDA Approval to Manufacture and Distribute Carprofen
4. MaxCyte to Present at BIO-Europe Spring 2008 Conference
5. Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences
6. Prometic to present at the American Chemical Society
7. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
8. Parks Associates Digital Health Analyst to Present Latest Research and Forecasts at ATA Show
9. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
10. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
11. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator (YI) ... of the Class of 2016 were selected from a pool of 128 applicants ... the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... Durham, NC (PRWEB) , ... June 23, 2016 , ... ... Odense University Hospital in Denmark detail how a patient who developed lymphedema after being ... (fat) tissue. The results could change the paradigm for dealing with this debilitating, frequent ...
Breaking Biology Technology:
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
Breaking Biology News(10 mins):